Clinical efficacy and safety of levofloxacin for mild-to-moderate community-acquired pneumonia
Claude Carbon, MD
Division des Maladies Infectieuses, Centre Hospitalier-Universitaire Vaudois, Lausanne, Switzerland
Levofloxacin has been demonstrated through several studies reviewed in this paper to be a safe, effective treatment of mild-to-moderately severe community-acquired pneumonia.(CAP) Its efficacy has been shown to be at least comparable to that of currently recommended first line antibiotics. A dose of 500 mg of levofloxacin once daily has been considered appropriate. In studies reporting its activity in CAP, levofloxacin has been shown to be well tolerated, and the strategy using levofloxacin as a first line choice is cost-effective. Caution in the use of fluoroquinolones for the treatment of respiratory tract infections is warranted, to reduce the risk of development of resistance of major pathogens such as Streptococcus pneumoniae.